New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
10:23 EDTSDT, GDOT, INSY, EXPE, DEPO, CPN, EZPW, BYIHigh option volume stocks
High option volume stocks: TTTN BYI EZPW CPN XEO DEPO EXPE INSY GDOT SDT
News For BYI;EZPW;CPN;DEPO;EXPE;INSY;GDOT;SDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
06:37 EDTEZPWStates relax personal loan restrictions, NY Times says
Subscribe for More Information
October 20, 2014
13:40 EDTBYIOptions with increasing implied volatility
Subscribe for More Information
12:24 EDTEZPWEZCORP recommended as long idea by Nikolayevsky, Bloomberg says
Bloomberg cites comments made by Anna Nikolayevsky of Axel Capital Management at the Robin Hood Conference.
October 17, 2014
10:51 EDTBYIOptions with increasing implied volatility
Options with increasing implied volatility: COV DISH HLT QEP GREK BKW BYI LLY DTV TIBX
October 16, 2014
09:02 EDTINSYInsys Therapeutics weakness creates buying opportunity, says JMP Securities
Subscribe for More Information
October 15, 2014
18:26 EDTINSYOn The Fly: After Hours Movers
Subscribe for More Information
16:34 EDTINSYInsys Therapeutics receives DEA approval to produce pharmaceutical Cannabidiol
Insys Therapeutics announced that its FDA inspected and Drug Enforcement Agency approved facility in Round Rock, Texas, has received DEA approval to manufacture synthetically its pharmaceutical grade Cannabidiol. The company has also been granted a quota to produce 15kg of CBD in 2014 and expects a larger quota in 2015 for its continued clinical studies. Insys believes these quantities are sufficient to pursue its CBD development program as currently planned. Insys held a pre-IND meeting with the FDA in September 2014 regarding its development program for CBD in pediatric patients suffering from Dravet Syndrome and Lennox-Gastaut Syndrome, two rare forms of pediatric epilepsy. Insys projects to file an IND in December 2014 for these indications. Babich also noted that Insys has compared its pharmaceutical CBD, which is synthetically produced, with plant-derived CBD obtained from the National Institute on Drug Abuse (NIDA), and found both materials contain an identical chemical structure. "We are pleased that testing in our laboratories has confirmed our long-standing belief that our pharmaceutical CBD is the chemical structure of plant-derived CBD and we believe our purity levels will provide consistent material in the clinical programs," Babich concluded.
16:31 EDTINSYInsys Therapeutics provides update on Dronabinol Oral Solution NDA
Subscribe for More Information
October 13, 2014
10:00 EDTEXPEExpedia October calls active on renewed takeover chatter
Subscribe for More Information
09:46 EDTEXPERumor: Expedia moves up on renewed takeover chatter
Shares of Expedia are moving higher on takeover speculation emanating from the following link. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use